Voya Investment Management LLC Grows Holdings in Prestige Consumer Healthcare Inc. $PBH

Key Points

• Voya Investment Management LLC increased its stake in Prestige Consumer Healthcare by 19.5% in the first quarter, owning approximately $3.59 million worth of shares.
• Prestige Consumer Healthcare reported a decrease in quarterly revenue of 6.6% year-over-year, with an EPS of $0.95, falling short of analysts' expectations.
• The company's stock has seen recent downgrades in analyst ratings, with Zacks Research lowering its rating from "hold" to "strong sell," as three analysts rate it as buy and three as hold.

Voya Investment Management LLC lifted its position in shares of Prestige Consumer Healthcare Inc. (NYSE:PBH - Free Report) by 19.5% during the first quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 41,717 shares of the company's stock after buying an additional 6,798 shares during the quarter. Voya Investment Management LLC owned approximately 0.08% of Prestige Consumer Healthcare worth $3,586,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also bought and sold shares of PBH. Opal Wealth Advisors LLC bought a new position in Prestige Consumer Healthcare in the 1st quarter worth approximately $38,000. Geneos Wealth Management Inc. increased its holdings in Prestige Consumer Healthcare by 92.8% in the 1st quarter. Geneos Wealth Management Inc. now owns 559 shares of the company's stock valued at $48,000 after acquiring an additional 269 shares during the last quarter. Costello Asset Management INC bought a new stake in Prestige Consumer Healthcare in the 1st quarter valued at $112,000. GAMMA Investing LLC increased its holdings in Prestige Consumer Healthcare by 35.9% in the 1st quarter. GAMMA Investing LLC now owns 1,879 shares of the company's stock valued at $162,000 after acquiring an additional 496 shares during the last quarter. Finally, KBC Group NV grew its position in shares of Prestige Consumer Healthcare by 7.4% during the first quarter. KBC Group NV now owns 2,199 shares of the company's stock valued at $189,000 after purchasing an additional 151 shares in the last quarter. 99.95% of the stock is owned by institutional investors.

Prestige Consumer Healthcare Stock Performance

Shares of NYSE PBH opened at $63.11 on Friday. The company has a current ratio of 4.38, a quick ratio of 2.99 and a debt-to-equity ratio of 0.55. The company has a 50 day simple moving average of $69.07 and a two-hundred day simple moving average of $78.49. Prestige Consumer Healthcare Inc. has a 12 month low of $61.93 and a 12 month high of $90.04. The stock has a market cap of $3.11 billion, a price-to-earnings ratio of 14.81, a PEG ratio of 2.03 and a beta of 0.46.

Prestige Consumer Healthcare (NYSE:PBH - Get Free Report) last issued its earnings results on Thursday, August 7th. The company reported $0.95 EPS for the quarter, missing analysts' consensus estimates of $1.01 by ($0.06). The company had revenue of $249.53 million during the quarter, compared to analysts' expectations of $260.71 million. Prestige Consumer Healthcare had a return on equity of 12.69% and a net margin of 19.02%.The firm's quarterly revenue was down 6.6% compared to the same quarter last year. During the same quarter in the previous year, the company earned $0.90 EPS. Prestige Consumer Healthcare has set its FY 2026 guidance at 4.500-4.580 EPS. As a group, analysts predict that Prestige Consumer Healthcare Inc. will post 4.5 earnings per share for the current year.

Analyst Ratings Changes

PBH has been the subject of a number of recent research reports. Canaccord Genuity Group dropped their price objective on shares of Prestige Consumer Healthcare from $105.00 to $100.00 and set a "buy" rating for the company in a research note on Friday, August 8th. Wall Street Zen downgraded Prestige Consumer Healthcare from a "buy" rating to a "hold" rating in a research report on Saturday, August 9th. Finally, Zacks Research lowered shares of Prestige Consumer Healthcare from a "hold" rating to a "strong sell" rating in a research note on Thursday, September 4th. Three research analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the company's stock. According to data from MarketBeat, the company presently has an average rating of "Hold" and a consensus price target of $93.33.

Prestige Consumer Healthcare Profile

Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.